Study title:
A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
Long title:
A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
Date receipt dossier:
24 Apr 2018
EudraCT number:
2017-004582-27
Company / Sponsor:
Bavarian Nordic A/S
Phase:
IIa
Treated organism:
Humans
Indication category:
Infectious disease
Disease:
Acute respiratory illness caused by RSV
Therapeutic approach:
Prevention
Genetic modification:
Vaccinia virus Ankara strain expression glycoproteins of different RSV strain (MVA-BN)
Method of transfer of nucleic acid of interest:
not applicable
Administered biological material:
Recombinant vaccinia virus (MVA-BN)
Route of administration:
Intramuscular
Locations in Belgium:
SGS Belgium NV
Type of procedure:
Contained use only
Current status:
Assessed